ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Coherus BioSciences Inc

Coherus BioSciences Inc (CHRS)

1.47
0.04
(2.80%)
Closed December 25 3:00PM
1.47
0.00
(0.00%)
After Hours: 3:39PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

CHRS News

Official News Only

CHRS Discussion

View Posts
MiamiGent MiamiGent 4 days ago
CHRS It seems to be a set it and forget it play. I'm in.
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 days ago
CHRS, under $2

๐Ÿ‘๏ธ0
MiamiGent MiamiGent 7 days ago
CHRS Phase 2 final data on Dec 18th.
Hero or Zero play.
Big short interest 27%. I'm long.
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 1 week ago
In sometime last week. Like the enthusiasm on this one.

๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 weeks ago
CHRS......................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 weeks ago
CHRS.............................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Shareing is winning Shareing is winning 3 weeks ago
Bought 30,000 in early November at .7232 = $21,696 spent, Blah Blah blah I am thinking cast a lot of 20,000 share since this turd is really going nowhere as planned. Maybe repurchase when it gets down to$1.25! 1000 lots at $1.50.
Just tired of watching before the WHALES show up!
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Loaded $1.70s again for another flip maybe sees closer to $3 this round
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 weeks ago
CHRS..........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
axelvento axelvento 3 weeks ago
Coherus Biosciences has completed the sale of Udenyca, which represents the third segment of its legacy biosimilar business. This deal comes after the company had previously divested other assets, including Cimerli and Yusimry.

The sale of Udenyca, which was projected to fetch around $400 million, or approximately twice its sales, has instead reached a potential value of $558 million, a figure that has positively surprised market observers.

The agreement to sell Udenyca also includes the elimination of Coherus Biosciences' convertible debt, which was due in 2026 and amounted to $230 million. The resolution of this debt is seen as a significant relief for the company, removing a previously contentious issue for shareholders and potentially attracting new investors who are focused on pure-play biotech companies without the looming concern of financing risks.
๐Ÿ‘๏ธ0
Shareing is winning Shareing is winning 3 weeks ago
easy reading while you wait FUTURE HOLD GOLD
Coherus BioSciences Inc. (CHRS) Overview
Company Name: Coherus BioSciences, Inc.
Ticker: CHRS
Exchange: Nasdaq Global Market (NasdaqGM)
Region: United States and Canada
Country: United States (US)
Industry: Biotechnology
CEO: Mr. Dennis M. Lanfear
Year Founded: 2010
Headquarters: Redwood City, California

Description:
Coherus BioSciences, Inc. is a biopharmaceutical company focusing on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, and has a pipeline that includes biosimilars of Humira, Avastin, and Lucentis. It also develops Toripalimab, an anti-PD-1 antibody for melanoma treatment in China, among other products. The company has several license agreements with notable firms like Selexis SA, AbbVie, Inc., Pfizer, Inc., and others.

Financial Metrics & Fundamentals
Market Cap: $157.84M
Total Enterprise Value (TEV): $330.03M
Total Revenues: $304.34M

Profitability:

Gross Profit Margin: 44.71%
EBITDA Margin: -38.42%
Operating Margin: -40.16%
Net Profit Margin: -0.15%
Pre-Tax Profit Margin: -0.15%
Per Share:

Revenue per Share: $2.68
EPS Diluted: -$0
Operating Cash Flow per Share: -$0.55
Free Cash Flow per Share: -$0.55
Capital Efficiency:

Return on Total Capital: -28.99%
Return on Capital Employed: -44.16%
Employees:

Total Employees: 235
Revenue per Employee: $1.14M
Gross Profit per Employee: $509.66K
Operating Profit per Employee: -$457.78K
Net Income per Employee: -$1.69K
Valuation:

P/E: -346.05
P/B: -1.79
EV/Sales: 1.08
EV/Gross Profit: 2.43
EV/EBITDA: -2.82
EV/FCF: 3.96
Forward Valuation:

Forward P/E: -5.53
Forward EV/Sales: 1.24
Forward EV/EBITDA: 118.25
Forward EV/FCF: -7.95
Growth:

Revenue 3Y CAGR: -5.76%
Revenue 5Y CAGR: 5.56%
Revenue 10Y CAGR: 27.97%
Diluted EPS 3Y CAGR: -89.17%
Diluted EPS 5Y CAGR: -53.06%
Diluted EPS 10Y CAGR: -56.79%
Recent Earnings Call Insights
Q3 2024 Results:

UDENYCA revenue grew 100% year-over-year to $66 million, maintaining its #2 position in the pegfilgrastim market with a 28% market share ([source], [source]).
Temporary supply interruption for UDENYCA, but packaging is resuming with 120,000 units expected to be completed over the next 5 weeks ([source], [source]).
Advancing immune-oncology pipeline, including Casdozokitug and CHS-114 ([source], [source]).
LOQTORZI saw 54% quarter-over-quarter revenue growth ([source], [source]).
Focused on disciplined financial management, reducing operating expenses, and improving gross margins ([source]).
๐Ÿ‘๏ธ0
Shareing is winning Shareing is winning 3 weeks ago
If this drops below $1.75 I'm in for another bunch maybe 500,000 just for Suppository's sake!
๐Ÿ‘๏ธ0
Shareing is winning Shareing is winning 3 weeks ago
https://ih.advfn.com/stock-market/NASDAQ/coherus-biosciences-CHRS/stock-news/95025208/form-defa14a-additional-definitive-proxy-solicit
๐Ÿ‘๏ธ0
Shareing is winning Shareing is winning 3 weeks ago
Pulled in 100,000 yesterday morning at 1.25 thought about selling half when it was at 2.35 range should have and waited to restock this afternoon.
when this hits 2.75 i am out!!!!!!!!!!
๐Ÿ‘๏ธ0
mugs57 mugs57 3 weeks ago
isn't the rule that a stock will run for 3 days before it takes a breather??
the cap value before getting the 500 mil was like 130 mil - we should at least see 2-3x the 1.30 starting price! go $CHRS!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 weeks ago
CHRS MONSTER BIO
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Back out 1.97
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Added 1.80s for the next flip
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Back in 1.90
๐Ÿ‘๏ธ0
mugs57 mugs57 3 weeks ago
45000 call options at jan $1 strike! you think someone knew something coming?? with this influx of cash stock could go to $5!!!
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Keep it simple $1.80s flippped at $1.96. Profit zone is $1.90- )2.85 expect some more lifting. Good luck 
๐Ÿ‘๏ธ0
tw0122 tw0122 3 weeks ago
Nice pick with the news getting rid of debt
f., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company NASDAQ: CHRS,) today announced that it has entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for the divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise for up to $558.4 million. This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Companyโ€™s $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.โ€œThe proposed divestiture of UDENYCA represents the successful execution of our strategy to focus R&D and commercial resources on Coherusโ€™ innovative immuno-oncology portfolio and to strengthen our financial position,โ€ said Denny Lanfear, Coherus Chairman and Chief Executive Officer. โ€œWe have created significant value with our UDENYCA franchise, and this proposed transaction allows us to monetize that value in order to maximize the opportunity ahead for LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor with growing sales and the only FDA-approved treatment for nasopharyngeal carcinoma (NPC), allowing us to accelerate and advance the development of our I-O pipeline in combination with LOQTORZI.โ€โ€œIn addition, by paying off our convertible notes in their entirety, we will significantly improve our capital structure and align our operational footprint with our strategic focus. As we enter this new phase of growth, we are well positioned to drive significant value for both patients and shareholders as we advance our mission to extend cancer patient survival.โ€
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 weeks ago
CHRS RUNNING
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 weeks ago
CHRS.....................................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 weeks ago
CHRS............................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 weeks ago
CHRS........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
mugs57 mugs57 4 weeks ago
anyone have any idea why the steady rise with volume?
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 weeks ago
CHRS.......................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 weeks ago
CHRS..................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 1 month ago
Nice day todaY...
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
https://schrts.co/sMeAHIGh

๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
 daily psar fliPPed to the Bullish Buy Sideโ€ฆ
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
76 after hoursโ€ฆ 
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
 aDDingโ€ฆ 
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
 back to greeNโ€ฆ 
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
Nice daily Bullish Engulfing candleโ€ฆ 
https://schrts.co/TkiuQvJe
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
inverted HammeR off the lower Keltner line, with the daily psar flip to the Bullish side quickly approaching; furthermore, pinching in here on the pincher 🤏 โ€ฆ  
https://schrts.co/IJcPqwzg
๐Ÿ‘๏ธ0
The GidDy uP Kid The GidDy uP Kid 2 months ago
...
๐Ÿ‘๏ธ0
boytroy88 boytroy88 2 months ago
It's even lower now. ☹️
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
CHRS new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
CHRS under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
CHRS under $2
๐Ÿ‘๏ธ0
glenn1919 glenn1919 5 months ago
CHRS...................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
CHRS under $3
๐Ÿ‘๏ธ0
frans frans 10 months ago
short interest about 28.000.000 milj.up 7% today
๐Ÿ‘๏ธ0
Mile High Marauder Mile High Marauder 11 months ago
Here is short interest link

https://www.nasdaq.com/market-activity/stocks/chrs/short-interest
๐Ÿ‘๏ธ0
frans frans 11 months ago
you know how many shorts we have here to cover ????
my last buy was 2.08
๐Ÿ‘๏ธ0
Mile High Marauder Mile High Marauder 11 months ago
I think selling these non core assets, with the probability of selling more has greatly diminished the need to raise money and has put some pressure on the shorts to cover some of this massive short. IMO
👍️ 1
frans frans 11 months ago
Coherusโ€™ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI™ (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor; and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates.

Closing is anticipated in from jan 22
๐Ÿ‘๏ธ0
Mile High Marauder Mile High Marauder 11 months ago
What fda news are u looking for?
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock